This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
CVS Health Steps Up to Bolster Oak Street as Cost Pressures Mount
by Moumi Mondal
CVS trims its outlook as Oak Street faces rising medical costs, but new leadership and tech upgrades aim for steady growth.
Arista Networks and Elevance Health have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Arista Networks shines with soaring sales and earnings beats, while Elevance Health cuts guidance and struggles in 2025.
Bear of the Day: Elevance Health (ELV)
by Derek Lewis
Lowered guidance has been a driving force behind the poor share performance, with EPS revisions remaining bearish.
New Strong Sell Stocks for September 15th
by Zacks Equity Research
CE, ELV and ARR have been added to the Zacks Rank #5 (Strong Sell) List on September 15, 2025.
Elevance Health Shrinks to Grow Stronger: From Part D to Plan B?
by Kaibalya Pravo Dey
ELV exits Part D and trims Medicare Advantage markets, betting on stronger-margin plans to protect profitability.
New Strong Sell Stocks for September 11th
by Zacks Equity Research
REFI, ELV and TAP have been added to the Zacks Rank #5 (Strong Sell) List on September 11, 2025.
UnitedHealth & AI: Can Technology Redefine Healthcare Efficiency?
by Zacks Equity Research
UNH is leveraging AI to streamline insurance and care delivery, aiming to boost efficiency and improve patient outcomes.
Cyberattack Hangover: Senators Question UnitedHealth's Loan Playbook
by Kaibalya Pravo Dey
Senators question UNH over tough loan repayment demands post-cyberattack, adding to regulatory and cost pressures.
CVS Health Sees Momentum in HCB Segment Amid Utilization Pressure
by Moumi Mondal
CVS' Health Care Benefit arm shines in Q2, driven by government plans, even as ACA exit and utilization pressures weigh.
Is ELV's Push Beyond Insurance a Blueprint for the Healthcare Future?
by Zacks Equity Research
Elevance Health expands beyond insurance into primary care, digital health and pharmacy services, aiming to reshape healthcare delivery.
Not Just Medicare, UnitedHealth's Optum Rx Gets Its Own DOJ Checkup
by Kaibalya Pravo Dey
UNH faces a widened DOJ probe, covering Optum Rx and physician payments, as rising medical costs pressure its business.
CVS vs. ELV: Which Healthcare Titan Is the Stronger Investment Today?
by Moumi Mondal
CVS Health advances with Aetna margin recovery, digital investments and cost savings, making it the stronger healthcare bet over Elevance.
UnitedHealth's Misdiagnosis: Can Berkshire's Bet Spark a Recovery?
by Kaibalya Pravo Dey
Berkshire's $1.57B bet on UNH sparks investor interest, but soaring costs, weak earnings and legal woes still cloud recovery hopes.
UnitedHealth Invests in Behavioral Health: A Bet on Future Demand?
by Zacks Equity Research
UNH expands behavioral health with Optum's digital tools, partnerships and integrated care to tap rising demand.
Can Elevance Health's Value-Based Care Strategy Fuel Long-Term Growth?
by Zacks Equity Research
ELV's focus on value-based care, Carelon integration and CareBridge acquisition drives membership and revenue growth.
UnitedHealth's Expansion Into ASCs: Redefining the Operating Room
by Zacks Equity Research
UNH is expanding its Optum surgery centers, cutting costs while boosting growth and patient access in value-based care.
CVS Gains in Pharmacy & Consumer Wellness Despite Reimbursement Woes
by Moumi Mondal
CVS Health's Pharmacy & Consumer Wellness unit posts double-digit revenue gains despite ongoing reimbursement headwinds.
Elevance Shoots for the Stars But Lands at 3.5: $375M Bonus Gone?
by Zacks Equity Research
Federal judge dismisses ELV's lawsuit challenging Medicare Advantage star ratings, leading to a $375M bonus loss tied to its star score.
UNH or ELV: Which Healthcare Titan Will Regain Investor Trust First?
by Kaibalya Pravo Dey
UnitedHealth and Elevance battle rising costs, but scale, Optum, and Buffett's backing give UNH the edge in restoring investor trust.
Danaher (DHR) Up 6.8% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Danaher (DHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
UnitedHealth's Push Into Home Health: A New Growth Chapter?
by Zacks Equity Research
UNH is expanding further into home health with Optum, fueled by a $3.3B Amedisys deal to boost value-based care growth.
Food as Medicine: Elevance Health & NACHC Integrate Nutrition in Care
by Zacks Equity Research
ELV partners with NACHC to bring Food as Medicine into primary care, targeting nutritional insecurities and chronic disease.
Buffett's Shot in the Arm Sends UnitedHealth Soaring Against the Odds
by Kaibalya Pravo Dey
Buffett's $1.57B bet on UNH sparks a 12% surge, lifting peers despite sector headwinds and recent struggles at the insurer.
When 90% Isn't an A+: Elevance's Cost Crunch and Carelon's Cushion
by Kaibalya Pravo Dey
ELV trims 2025 outlook as medical costs climb, but commercial growth and Carelon's momentum aim to steady performance.
Can UnitedHealth Really Fight Cost Headaches With $3.3B Amedisys Pill?
by Kaibalya Pravo Dey
UNH's $3.3B Amedisys deal will likely clear DOJ hurdles with divestitures, aiming to tap fast-growing home healthcare amid rising cost pressures.